Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seventeen ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, thirteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $56.58.
FTH has been the subject of several research analyst reports. Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a research note on Monday, November 16th. TD Cowen started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Finally, Citigroup upped their price target on shares of Sensei Biotherapeutics from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics during the first quarter worth approximately $22,758,000. Candriam S.C.A. acquired a new stake in Sensei Biotherapeutics in the third quarter worth approximately $9,542,000. State Street Corp bought a new position in Sensei Biotherapeutics during the 3rd quarter valued at $9,262,000. Integral Health Asset Management LLC bought a new position in Sensei Biotherapeutics during the 3rd quarter valued at $7,138,000. Finally, Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the 2nd quarter valued at $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.
Sensei Biotherapeutics Stock Performance
NASDAQ:FTH opened at $7.86 on Friday. Sensei Biotherapeutics has a 1 year low of $7.45 and a 1 year high of $42.14. The company has a market capitalization of $203.10 million, a PE ratio of -0.06 and a beta of -0.15. The stock has a fifty day simple moving average of $22.10.
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). Equities analysts expect that Sensei Biotherapeutics will post -14.01 EPS for the current fiscal year.
About Sensei Biotherapeutics
Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.
See Also
- Five stocks we like better than Sensei Biotherapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
